Riverside Health System's primary responsibility is service to and care of those who trust us to help shape their healthcare choices.  

Riverside engages in clinical research to provide health options that may not otherwise be available through standard medical channels. Clinical trials for medications and procedures offer additional resources for health challenges, and contribute to the advancement of medicine. One of the clinical trials currently underway at Riverside that is actively recruiting patient participation is: 

Secondary Progressive Multiple Sclerosis (SPMS)

There are currently no FDA-approved treatments for secondary progressive MS and people affected urgently need help. With SPMS there are daily living challenges that often worsen with each flare up, including trouble walking, dealing with pain, fatigue and increased memory issues. A potential treatment option is on the horizon with Riverside's Hampton Roads Neurology as one of only 30 sites in the U.S. and Canada participating in a clinical trial to study an investigational therapy. This therapy uses a patient's own immune cells to help stabilize or stop the progression of the disease. Study participants must be 18-60 years of age, be willing to discontinue current MS therapy, be able to walk with nothing more than a cane and have progression of their MS within the past two years. For additional details, contact us at the (757) 534-5374 or email the Research Coordinator, Cheryl White, at cheryl.white@rivhs.com.